Business Description

Sage Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
SG7.GermanySAGE.USA Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 101.23 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 13.61 | |||||
Beneish M-Score | 82.97 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -61.9 | |||||
3-Year EBITDA Growth Rate | 2.9 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year FCF Growth Rate | -4.1 | |||||
3-Year Book Growth Rate | 16.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 26.39 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.89 | |||||
9-Day RSI | 65.5 | |||||
14-Day RSI | 62.92 | |||||
6-1 Month Momentum % | -3.96 | |||||
12-1 Month Momentum % | -8.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.7 | |||||
Quick Ratio | 14.7 | |||||
Cash Ratio | 13.98 | |||||
Days Payable | 3355.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 88.29 | |||||
Operating Margin % | -8022.48 | |||||
Net Margin % | -7895.27 | |||||
ROE % | -31.63 | |||||
ROA % | -29.86 | |||||
ROIC % | -1676.93 | |||||
ROC (Joel Greenblatt) % | -2940.72 | |||||
ROCE % | -31.95 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 420.87 | |||||
PB Ratio | 2.01 | |||||
Price-to-Tangible-Book | 2.01 | |||||
EV-to-EBIT | -2.58 | |||||
EV-to-EBITDA | -2.59 | |||||
EV-to-Forward-EBITDA | -2.07 | |||||
EV-to-Revenue | 207.33 | |||||
EV-to-Forward-Revenue | 15.65 | |||||
EV-to-FCF | -3.11 | |||||
Price-to-Net-Current-Asset-Value | 2.04 | |||||
Price-to-Net-Cash | 2.15 | |||||
Earnings Yield (Greenblatt) % | -38.76 |
How Sage Therapeutics Inc (SAGE) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SAGE
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 6.464 | ||
EPS (TTM) ($) | -8.63 | ||
Beta | 1.04 | ||
Volatility % | 27.88 | ||
14-Day RSI | 62.92 | ||
14-Day ATR ($) | 1.871726 | ||
20-Day SMA ($) | 43.63475 | ||
12-1 Month Momentum % | -8.22 | ||
52-Week Range ($) | 27.36 - 49.56 | ||
Shares Outstanding (Mil) | 59.49 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sage Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Sage Therapeutics Inc Stock Events
Event | Date | Price($) | Daily Change % | ||
---|---|---|---|---|---|
No Event Data |
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |